Skip to main content

Research Repository

Advanced Search

All Outputs (12)

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2023)
Preprint / Working Paper
Abhishek, A., Grainge, M. J., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., …Riley, R. D. Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation

Background Sulfasalazine induced cytopenia, nephrotoxicity, and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend three monthly monitoring blood-tests indefinitely while others recommend stopping monitoring after one ye... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., …Study investigators, V. (2024). Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial. The Lancet Rheumatology, 6(2), E92-E104. https://doi.org/10.1016/S2665-9913%2823%2900298-9

Background Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv... Read More about Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial.

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., …Cook, J. A. (2023). Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial. The Lancet Rheumatology, 6(2), e92-e104. https://doi.org/10.1016/s2665-9913%2823%2900298-9

Background: Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv... Read More about Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

How do clinicians prescribe bridging glucocorticoids in people starting or escalating disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a service evaluation survey (2023)
Journal Article
Prior, J. A., Roddy, E., Solis-Trapala, I., Cornwall, N., Jinks, C., Abhishek, A., …Hider, S. (2023). How do clinicians prescribe bridging glucocorticoids in people starting or escalating disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a service evaluation survey. Rheumatology Advances in Practice, 7(3), Article rkad102. https://doi.org/10.1093/rap/rkad102

Diagnosis of calcium pyrophosphate crystal deposition disease by ultrasonography: how many and which sites should be scanned? (2023)
Journal Article
Cipolletta, E., Moscioni, E., Sirotti, S., Di Battista, J., Abhishek, A., Rozza, D., …Filippucci, E. (2023). Diagnosis of calcium pyrophosphate crystal deposition disease by ultrasonography: how many and which sites should be scanned?. Rheumatology, https://doi.org/10.1093/rheumatology/kead565

Objective To develop the optimal US scanning protocol for the diagnosis of CPPD disease. Methods In this cross-sectional study, consecutive patients with a crystal-proven diagnosis of CPPD disease, and age-, sex-matched disease controls and... Read More about Diagnosis of calcium pyrophosphate crystal deposition disease by ultrasonography: how many and which sites should be scanned?.

Impact of Frailty on Emergency Department Encounters for Cardiovascular Disease: A Retrospective Cohort Study (2023)
Journal Article
Sokhal, B. S., Matetić, A., Abhishek, A., Banerjee, A., Partington, R., Roddy, E., …Mamas, M. A. (2023). Impact of Frailty on Emergency Department Encounters for Cardiovascular Disease: A Retrospective Cohort Study. American Journal of Cardiology, 206, 210-218. https://doi.org/10.1016/j.amjcard.2023.08.138

Data are limited on whether the causes of emergency department (ED) encounters for cardiovascular diseases (CVDs) and associated clinical outcomes vary by frailty status. Using the United States Nationwide ED Sample, selected CVD encounters (acute my... Read More about Impact of Frailty on Emergency Department Encounters for Cardiovascular Disease: A Retrospective Cohort Study.

The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease (2023)
Journal Article
Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., …Choi, H. K. (2023). The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Annals of the Rheumatic Diseases, 82(10), 1248-1257. https://doi.org/10.1136/ard-2023-224575

Objective Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have develop... Read More about The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease.

The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease (2023)
Journal Article
Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., …Choi, H. K. (2023). The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis and Rheumatology, 75(10), 1703-1713. https://doi.org/10.1002/art.42619

Objective Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have deve... Read More about The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.

The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease (2023)
Journal Article
Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., …Choi, H. K. (2023). The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis and Rheumatology, 75(10), 1703-1713. https://doi.org/10.1002/art.42619

Objective Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have develo... Read More about The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.

Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease (2023)
Journal Article
Cipolletta, E., Abhishek, A., Di Matteo, A., Grassi, W., & Filippucci, E. (2023). Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease. RMD Open, 9(1), Article e002940. https://doi.org/10.1136/rmdopen-2022-002940

Objective To test whether the double contour (DC) sign has a different dynamic behaviour in gout and calcium pyrophosphate deposition (CPPD) and whether the dynamic assessment of the DC sign increases its accuracy in gout diagnosis. Methods This cros... Read More about Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease.

Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD (2023)
Journal Article
Card, T. R., Nakafero, G., Grainge, M. J., Mallen, C. D., Van-Tam, J. S. N., Williams, H. C., & Abhishek, A. (2023). Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD. American Journal of Gastroenterology, 118(8), 1388-1394. https://doi.org/10.14309/ajg.0000000000002205

INTRODUCTION: To investigate the association between vaccination against coronavirus disease 2019 (COVID-19) and inflammatory bowel disease (IBD) flare. METHODS: Patients with IBD vaccinated against COVID-19 who consulted for disease flare be... Read More about Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.